Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND Patients with type 2 diabetes (T2D) are at increased risk of both cardiovascular disease (CVD) and advanced liver fibrosis related to non-alcoholic fatty liver disease (NAFLD). Statin use is known to reduce the incidence of CVD while evidence on an effect on NAFLD severity is limited. METHODS This is a cross-sectional study performed with data from the 2017-2018 cycle of the National Health and Nutrition Examination Survey (NHANES). The target population consisted in adult patients with T2D and reliable vibration-controlled transient elastography (VCTE) results. Presence of liver fibrosis and steatosis were assessed by the median values of liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), respectively. Patients with evidence of viral hepatitis and significant alcohol consumption were excluded. Logistic regression analysis was performed to evaluate the association between statin treatment and both steatosis and advanced (≥F3) liver fibrosis after adjustment for potential confounders. RESULTS The study population consisted in 744 patients (age: 61 ± 1 years, BMI: 33.3 ± 0.5 Kg/m2). NAFLD (CAP≥274 dB/m) was present in 74.9% of patients (95% CI 69.2-79.8) and 14.5% (95% CI 10.8-19.2) had advanced fibrosis (LSM ≥ 9.6 KPa). After adjustment for age, sex, race-ethnicity, BMI, albumin, total cholesterol, HbA1c, triglycerides and liver enzymes, statin use was associated with lower odds of advanced fibrosis (OR 0.35, 95% CI 0.13-0.90, p = 0.03). No significant interaction was found between statin use and steatosis. CONCLUSION Given the absence of approved therapies for NAFLD-fibrosis, it would be reasonable to initiate specific randomized controlled trials with statins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
Cited by
NAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 405
Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study
Ayada, I., van Kleef, L. A., Zhang, H., Liu, K., Li, P., Abozaid, Y. J., Lavrijsen, M., Janssen, H. L. A., van der Laan, L. J. W., Ghanbari, M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2022.104392 · Cited by 117
Xie, R., & Liu, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.857110 · Cited by 98
Recent research advances in metabolism, clinical and experimental
Boutari, C., Kokkorakis, M., Stefanakis, K., Valenzuela-Vallejo, L., Axarloglou, E., Volčanšek, Š., Chakhtoura, M., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155722 · Cited by 9
Metadata
- Authors
- Ciardullo, S., & Perseghin, G.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 121
- Pages
- 154752
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W3137342104
- Cited by
- 110
- References
- 11
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1016/j.metabol.2021.154752
- The paper
- Ciardullo, S., & Perseghin, G. (2021). Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism. https://doi.org/10.1016/j.metabol.2021.154752
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.